---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006171"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:08:07.412355+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort

## Summary
- Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.
- PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.
- July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.
- R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs.

## SEC filing metadata
- accession: 0001683168-25-006171
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/0001683168-25-006171-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825006171/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006171
- JSON: https://secwatch.observer/filing/0001683168-25-006171.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006171.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.